Results 161 to 170 of about 62,547 (255)

Proton-pump inhibitors and palbociclib or abemaciclib in endocrine-sensitive breast cancer treatment. [PDF]

Sci Rep
Takada S, Takahashi K, Uozumi R, Mukohara T, Hayashida T, Iwabe M, Iihara H, Kusuhara-Mamishin K, Tahatsu K, Kitagawa Y, Tsuchiya M, Kitahora M, Umehara K, Nagayama A, Kosaka S, Asano-Niwa Y, Watanabe K, Seki T, Ohnuki K, Futamura M, Kawazoe H, Nakamura T.   +21 more
europepmc   +1 more source

Altered Pathogen Spectrum of Spontaneous Bacterial Peritonitis in Patients Treated With Proton Pump Inhibitors. [PDF]

Aliment Pharmacol Ther
Kitchen P, Schütte SL, Tergast TL, Maasoumy B, Braun L, Esche UVD, Häcker G, Mücke MM, Reincke M, Schultheiss M, Thimme R, Rieg S, Bettinger D, Sturm L.   +13 more
europepmc   +1 more source

Proton pump inhibitors and the risk of urolithiasis: A Mendelian randomization study. [PDF]

Medicine (Baltimore)
Guo J, Chen X, Dou Y, Xiong Y, Zhao T.
europepmc   +1 more source

Impact of proton pump inhibitors on immunotherapy is modulated by prior chemotherapy and linked to gut microbiome-immune cell signatures. [PDF]

Cancer Immunol Immunother
Petouhoff A, Hicks R, Husain M, Hoyd R, Xu M, Dravillas C, Patel SH, Johns A, Grogan M, Li M, Lopez G, Miah A, Liu Y, Muniak M, Schmidt M, Das A, Lathrop H, Das P, Secor A, Haddad T, Tinoco G, Carbone D, Kendra K, Otterson GA, Presley CJ, Mace T, Spakowicz D, Owen DH.   +27 more
europepmc   +1 more source

Response to Proton-Pump Inhibitors Therapy in Pediatric Patients With Eosinophilic Esophagitis in Bogotá, Colombia. [PDF]

Can J Gastroenterol Hepatol
Rodríguez López AE, Vera Chamorro JF, Carias Domínguez AM, Pinilla Roncancio MV, López Panqueva RDP, Montaño Rozo GA.   +5 more
europepmc   +1 more source

Proton Pump Inhibitors and Risk of Chronic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]

Cureus
Almabruk BA, Alsulami GA, Alzahrani A, Alsulami EA, Badawood AA, Alghanim AS, Alresheedi FF, Alharbi RS, Alghamdi HA.   +8 more
europepmc   +1 more source

Effect of Butyrate-Producing Enterobacteria and Proton Pump Inhibitors on Advanced Hepatocellular Carcinoma Treatment With Durvalumab and Tremelimumab. [PDF]

JGH Open
Nouso K, Wakuta A, Shiota S, Fujita R, Kariyama K, Hiraoka A, Atsukawa M, Tani J, Tada T, Nakamura S, Tajiri K, Kaibori M, Hirooka M, Itobayashi E, Kakizaki S, Naganuma A, Ishikawa T, Imai M, Aoki T, Tanaka H, Hatanaka T, Tsuji K, Kawata K, Takaguchi K, Tsutsui A, Ogawa C, Ochi H, Yata Y, Kuroda H, Matono T, Yasuda S, Toyoda H, Iijima H, Kudo M, Kumada T.   +34 more
europepmc   +1 more source

Proton Pump Inhibitors: How Appropriate?

Canadian Journal of Gastroenterology, 2000
Daniel C Sadowski
doaj   +1 more source

Association Between the Use of Proton Pump Inhibitors and Osteoporosis/Fracture: Nested Case-Control Studies Using a National Health Screening Cohort. [PDF]

J Clin Med
Youk H, Park JM, Kim YJ, Park JY, Choi HG, Lee JW.   +5 more
europepmc   +1 more source

Risk of Depression Related to Use of Proton Pump Inhibitors and Tegoprazan: A Nationwide Cohort Study. [PDF]

J Korean Med Sci
Kim S, Kim JS.
europepmc   +1 more source